Trial reportThe American journal of clinical nutrition2025
Effects of a palmitoleic acid concentrated oil on C-reactive protein levels in adults: A randomized, double-blind placebo-controlled clinical trial.
Trial report in The American journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Palmitoleic acid content and composition-based nutritional quality of commercial omega-7 oils and supplements.Frontiers in nutrition · 2026Article
- Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPalmitoleic acid (POA) is an n-7 monounsaturated fatty acid. Preclinical studies suggest cis-POA lowers inflammation and improves metabolism. However, the impact of POA supplementation on inflammatory/metabolic biomarkers in humans is not well understood.
objectivesThe primary aim was to investigate if cis-POA lowers circulating high-sensitivity C-reactive protein (hs-CRP) relative to placebo. Secondary endpoints were interleukin-6, tumor necrosis factor-α, fasting glucose, insulin, glycosylated hemoglobin, low-density lipoprotein cholesterol, red blood cell (RBC), and plasma fatty acid concentration. Exploratory endpoints were total cholesterol, high-density lipoprotein cholesterol, triglycerides, leptin, ghrelin, peptide YY, and adiponectin.
methodsThe randomized double-blinded parallel arm trial enrolled 123 participants with hs-CRP concentrations of 2 mg/L or higher. Participants consumed 500 mg/d or 1000 mg/d of marine-source POA or placebo for 12 wk. Fasting blood draws were used to quantify plasma inflammatory/metabolic biomarkers at baseline and 12-wk by multiplex immunoassays. Plasma and RBC POA concentrations were quantified with gas chromatography. Dietary intake was assessed with the Nutrition Data System for Research. Analysis of covariance analysis was used to investigate if there is an effect of either baseline or dosage on inflammatory/metabolic biomarkers.
resultsAt baseline, all 3 groups had similar hs-CRP concentrations [geometric mean (standard deviation) = 0.57 (0.17), 0.54 (0.20), and 0.53 (0.23)] at 1000 mg/d, 500 mg/d, and placebo, respectively. There were no changes in hs-CRP concentration within and between the 3 groups in response to the supplementation. Analysis of covariance analysis showed there was no significant influence of baseline hs-CRP or POA dosage on changes in hs-CRP. There were also no changes in secondary or exploratory endpoints in response to placebo or POA. Significant changes were measured in select plasma and RBC fatty acids that were significantly related to POA dosage (P < 0.001) but not baseline.
conclusionsCompared to placebo, supplementation for 12 wk with 500 mg/d or 1000 mg/d POA did not significantly lower hs-CRP or change other biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.